SR-9009 (Stenabolic) + GW-0742 (Fitorine) | Metabolic Research UK

Metabolic Recomposition Research Set

The BioPlex Metabolic Recomposition Research Set combines SR-9009 (Stenabolic) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together two synthetic research compounds associated with distinct molecular pathways involved in metabolic regulation. The set contains one pot of each compound and provides a structured format for comparative laboratory investigation of REV-ERB-associated and PPARδ-associated signalling within a broader metabolic research framework. 

Neither SR-9009 nor GW-0742 is a selective androgen receptor modulator. This distinction is important because both compounds are sometimes commercially grouped alongside SARMs despite operating through fundamentally different areas of molecular research. SR-9009 was developed during research into REV-ERB nuclear receptors and has been investigated across circadian, transcriptional and metabolic experimental models. GW-0742 is associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ, and has been used experimentally to investigate lipid metabolism, cellular signalling and other PPAR-regulated pathways.

This difference creates the principal scientific interest of the pairing. Instead of examining two compounds directed toward the same receptor, researchers can compare separate regulatory pathways that intersect with broader questions concerning cellular metabolism and gene expression.

The Metabolic Recomposition Research Set name reflects this shared research theme rather than implying that either compound produces a predetermined physiological result. Metabolic regulation involves interconnected receptor systems, transcription factors, enzymes and cellular responses, making controlled experimental interpretation essential.

By bringing SR-9009 and GW-0742 together while maintaining clear separation between their mechanisms, BioPlex provides a comparative research format for investigating two distinct metabolic-signalling compounds. Both products remain individually identified 50×15mg capsule compounds supplied strictly for laboratory, analytical and educational research.

How SR-9009 and GW-0742 Work Together

SR-9009 (Stenabolic) and GW-0742 (Fitorine) are scientifically interesting as a research pairing because they are associated with different nuclear-receptor pathways connected to metabolic regulation. Rather than sharing a single molecular target, the compounds provide two separate experimental approaches for examining transcriptional and cellular processes involved in metabolism.

SR-9009 was originally developed and investigated as a synthetic ligand associated with REV-ERBα and REV-ERBβ. REV-ERB proteins are nuclear receptors involved in transcriptional networks connecting circadian timing with metabolic regulation. Experimental investigation of SR-9009 has consequently examined circadian behaviour, metabolic gene expression, mitochondrial-associated processes and energy-related cellular pathways.

GW-0742 is associated primarily with PPARδ, another nuclear receptor involved in transcriptional regulation. PPARδ participates in biological pathways associated with lipid handling, fatty-acid metabolism and cellular energy regulation. Experimental PPARδ agonists have therefore become useful tools for investigating how receptor activation influences downstream transcription and metabolic markers.

Placing the two compounds together allows researchers to consider these separate pathways within a common metabolic research framework. REV-ERB-associated signalling can be investigated alongside PPARδ-associated signalling while maintaining compound-specific controls and endpoints.

This does not establish that SR-9009 and GW-0742 are synergistic or that one compound enhances the activity of the other. The pathways are biologically complex, and observed responses may vary substantially according to experimental model, concentration, exposure and cellular environment.

There are also mechanistic limitations to consider. Later SR-9009 research has raised questions about whether all observed effects are dependent exclusively on REV-ERB, making careful interpretation particularly important.

The value of the pairing therefore lies in comparative pathway investigation: two different synthetic compounds, two distinct areas of nuclear-receptor research and a shared broader interest in metabolic regulation.

SR-9009 (Stenabolic) 50×15mg

SR-9009, commonly known as Stenabolic, is a synthetic research compound originally developed during investigation of REV-ERBα and REV-ERBβ nuclear receptors. Despite frequently appearing alongside SARMs within commercial research-compound categories, SR-9009 is not a selective androgen receptor modulator and should not be described as acting primarily through androgen-receptor signalling.

REV-ERB proteins participate in transcriptional networks connecting circadian regulation with metabolic processes. These nuclear receptors form part of the molecular machinery involved in controlling patterns of gene expression over biological time cycles while also interacting with pathways associated with cellular metabolism.

Early research involving SR-9009 investigated whether synthetic pharmacological modulation of REV-ERB-associated pathways could influence measurable metabolic and circadian endpoints. This generated experimental interest in metabolic gene expression, mitochondrial-associated activity, energy regulation and related biological markers.

However, subsequent research introduced an important qualification. Experimental work has reported SR-9009-associated effects in systems where functional REV-ERB activity was absent or disrupted. These observations suggest that at least some responses associated with SR-9009 may occur through mechanisms that are not exclusively dependent upon REV-ERB.

This means SR-9009 remains useful as an experimental compound while requiring greater care when interpreting mechanism. An observed response following exposure should not automatically be treated as proof of direct REV-ERB-mediated activity.

Within the Metabolic Recomposition Research Set, SR-9009 therefore provides the REV-ERB-associated side of the pairing. Its research history can be compared with the distinctly different PPARδ-associated profile of GW-0742.

This arrangement enables researchers to examine separate metabolic-signalling pathways within the same broader experimental theme while retaining appropriate controls, compound-specific interpretation and clear distinction between observed responses and proposed molecular mechanisms.

GW-0742 (Fitorine) 50×15mg

GW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, usually abbreviated PPARδ. This classification separates GW-0742 from genuine selective androgen receptor modulators because its principal research pathway involves a different member of the nuclear-receptor superfamily.

PPARδ functions as a transcriptional regulator. Following ligand interaction, PPAR-associated signalling can influence expression of genes involved in several metabolic and cellular processes. PPARδ research has consequently included investigation of lipid metabolism, fatty-acid handling, cellular energy regulation and other receptor-dependent biological pathways.

GW-0742 has been used experimentally as a pharmacological tool for studying PPARδ-associated activity. Its value in laboratory research comes from allowing investigators to examine how modulation of this receptor corresponds with changes in predetermined molecular or cellular endpoints.

However, receptor classification should not be interpreted as guaranteeing a particular biological result. Experimental observations depend upon concentration, exposure, receptor expression, tissue or cell type and methodology. Potential off-target activity and model-specific responses also need to be considered when drawing mechanistic conclusions.

Within the BioPlex Metabolic Recomposition Research Set, GW-0742 provides a distinctly different molecular pathway from SR-9009. Whereas SR-9009 is associated historically with REV-ERB research, GW-0742 provides a PPARδ-focused experimental compound.

This distinction makes the pairing particularly useful for comparative metabolic research. Researchers can examine two separate nuclear-receptor-associated pathways without incorrectly assuming that the compounds possess identical mechanisms.

The purpose of the pairing is therefore not to claim an enhanced combined effect. Instead, GW-0742 and SR-9009 provide two research tools for investigating different aspects of transcriptional and metabolic signalling under controlled laboratory conditions.

Explore Related Research Compounds

Continue exploring related metabolic and cellular-signalling research compounds from the BioPlex range.

View SR-9009 Stenabolic 50×15mg Research Capsules ⟶

View GW-0742 Fitorine 50×15mg Research Capsules ⟶

Explore All BioPlex SARMs & Related Research Compounds ⟶

Explore BioPlex Research Information

Access BioPlex research guidance, compound classification and the complete research product range.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore the BioPlex SARMs & Research Compound Range ⟶

View All BioPlex Research Products ⟶

Explore Related Research Articles

Continue your research with BioPlex articles covering metabolic research compounds, compound classification and molecular pathways distinct from conventional androgen-receptor SARMs.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore BioPlex SARMs & Research Compound Articles ⟶

Disclaimer

For research purposes only. Not for human consumption.